Big Review Rattles Antidepressant Rankings

Hands exchanging a blister pack of capsules at a pharmacy counter
Photo: GBJSTOCK / Shutterstock

A massive new review of antidepressant trials says three common drugs may keep depression away longer than one of the most prescribed medicines on the market.

Quick Take

  • Researchers reviewed 115 clinical trials with more than 30,000 participants to compare antidepressants head-to-head.
  • Escitalopram, duloxetine, and agomelatine showed a better chance of sustained response than fluoxetine.
  • People on escitalopram or duloxetine were also less likely to quit the trials early.
  • The researchers call their own findings “far from definitive,” and most trials only tracked patients for about six months.

What The Large Review Actually Found

Scientists pulled together 115 randomized controlled trials for this review, covering more than 30,000 people who took antidepressants. Instead of just comparing drugs to a sugar pill, the team focused on 35 trials that pitted one real antidepressant against another. That head-to-head approach is rare in depression research, and it gives doctors a clearer picture of how these drugs stack up against each other, not just against nothing.

Three drugs stood out. Escitalopram, duloxetine, and agomelatine were all linked to a greater chance that patients stayed well over time, compared to fluoxetine. Fluoxetine, sold for decades under brand names like Prozac, is one of the most familiar antidepressants in America. Finding that newer options may outperform it on staying power is a meaningful signal for prescribers weighing long-term treatment plans.

Why Sticking With Treatment Matters

The review also tracked who dropped out of these trials altogether. Patients taking escitalopram or duloxetine stuck with treatment more often than those on fluoxetine. That matters because a drug cannot help anyone who stops taking it. Lower dropout rates suggest better tolerability, fewer harsh side effects, or simply a treatment plan patients found easier to live with day to day.

Still, dropout numbers alone do not prove a drug controls depression symptoms better over years. Patients quit medications for many reasons, including cost, side effects, or feeling better and assuming they no longer need it. A trial measuring who quit is not the same as a trial measuring who stayed symptom-free. That distinction matters for anyone reading headlines about “sustained response”.

The Researchers’ Own Caution Deserves Attention

The scientists behind this review did not oversell their results. They stated plainly that their findings suggest some antidepressants may work better than others, but that the evidence remains far from settled. More than half the studies in the main comparison carried a high risk of bias, meaning flaws in design or reporting could have skewed the outcomes in ways researchers cannot fully correct for.

Word choice matters here too. The review labeled anything six months or longer as “long term,” yet most of the head-to-head trials only followed patients for roughly six months. Only six trials tracked people longer than that. For a disease that often requires years of management, six months tells doctors something useful, but it is not the multi-year proof many patients assume when they hear the phrase “long term”.

How This Fits The Bigger Antidepressant Debate

This review lands in a field that has produced mixed messages for years. One earlier study found antidepressants were not linked to better overall quality of life for long-term users, while another described the drugs as generally safe based on existing data. A 2007 review of 293 studies found little difference in short-term effectiveness among a dozen common antidepressants, though side effects varied enough to drive doctors toward different prescriptions.

Taken together, these findings do not contradict each other so much as answer different questions. One study might measure symptom relief after a few weeks. Another measures who stays in treatment after six months. A third looks at quality of life years later. Readers deserve to know which question a headline is actually answering before assuming any single study settles the matter on antidepressants broadly.

For now, the practical takeaway is narrower than “which antidepressant works best.” It is that escitalopram, duloxetine, and agomelatine showed an edge over fluoxetine in sustaining response and keeping patients in treatment, based on the best head-to-head data available today. Patients and doctors weighing these options still have real decisions to make, informed by this data but not dictated by it.

Depression treatment remains deeply personal, shaped by a patient’s history, other health conditions, and how their body responds to any given drug. This review gives doctors one more solid data point, built on a far larger sample than most past comparisons. It does not replace the judgment of a physician who knows a patient’s full medical picture.

Sources:

sciencedaily.com